Navigation Links
Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Date:2/18/2009

(53,595) (881,160) Interest expense on convertible notes (571,808) (67,836) (1,005,962) Net Loss $(2,805,747) $(1,431,884) $(33,028,777) Basic and Diluted Net Loss Per Common Share $(0.15) $(0.08) Basic and Diluted Weighted Average Number of Common Shares Outstanding 18,504,477 17,474,282

                        SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY
                               (A DEVELOPMENT STAGE COMPANY)
                           CONDENSED CONSOLIDATED BALANCE SHEETS

                                                    December 31,    June 30,
                                                        2008          2008
                                                    (unaudited)
                         ASSETS

    CURRENT ASSETS:
    Cash and cash equivalents                        $1,115,788    $5,676,985
    Short-term investments                            2,500,000       500,000
    Prepaid expenses and other current assets           828,919       180,556
       Total Current Assets                           4,444,707     6,357,541

    Property and equipment, net                           3,893         5,459
    Intangibles, net                                  3,515,565     3,213,543
    Deferred financing costs                            847,385     1,059,230
    Security deposit                                      7,187         7,187
       TOTAL ASSETS                                  $8,818,737   $10,642,960

          LIABILITIES AND STOCKHOLDERS' EQUITY

    CURRENT LIABILITIES:
    Accounts payable                                   $468,280      $370,167
    Accrued expenses                                    413,684       314,267
           Total Current Liabilities                    881,964       684,434

    Convertible note, net of discount        
'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
2. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
3. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
5. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
6. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
7. Senesco Technologies to Present at BIO 2008 Business Forum
8. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of ... to announce the relaunch of his highly informative blog, now ... called “ What are Stem Cells ?” Dr. Harman’s ... foundation in the basics of stem cell therapy so that ... type of treatment when considering regenerative medicine. , A veterinarian ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... a significant percentage of Americans, the answer is no, ... the science of the very small. , Addressing scientists ... of the American Association for the Advancement of Science, ... sciences communication, presented new survey results that show religion ...
... that Significantly Raises HDL "Good" Cholesterol and Lowers ... ... ABBOTT PARK, Ill., Feb. 15 Today, Abbott,received U.S. Food and ... widely prescribed cholesterol,therapies, Niaspan(R) (Abbott,s proprietary niacin extended-release) and,simvastatin. SIMCOR is ...
... Pharma (Oxford, UK), a,Vaccinex collaboration partner, has announced ... discovered by Vaccinex, to,GlaxoSmithKline., According to the ... an up-front,license fee, development milestones, and royalties on ... develop and commercialize,OP-R003 for the treatment of rheumatoid ...
Cached Biology Technology:Religion colors Americans' views of nanotechnology 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 3Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 4Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 5Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 6Vaccinex Antibody Licensed to GlaxoSmithKline 2
(Date:7/11/2014)... that transplantation of mesenchymal stem cells can stimulate neurogenesis ... of Alzheimer,s disease (AD) and improve tissue and function ... are reported on the therapeutic effect of adipose-derived stem ... the effect on oxidative injury and neurogenesis in the ... team, School of Life Sciences, Tsinghua University, China transplanted ...
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
Breaking Biology News(10 mins):
... factor only just beginning to be appreciated by social ... Terje Tvedt, of the Universities of Oslo and Bergen, ... role in shaping societies throughout human history. Speaking at ... in October, Tvedt proposed that social scientists and historians ...
... vice president for technology development at NJIT, has been ... and Technology to assist faculty researchers with the most ... $50,000. The money, known as Gap grants, is ... idea and a commercial product. Sixteen grants ...
... Carolina at Chapel Hill researchers using brain imaging of ... that may mark the onset of autistic symptoms is ... in funding. , The Infant Brain Imaging Study ... awarded $10 million in 2007 by the National Institutes ...
Cached Biology News:Using water to understand human society, from the industrial revolution to global trade 2Using water to understand human society, from the industrial revolution to global trade 3Moving new technologies from the lab to the marketplace 2Moving new technologies from the lab to the marketplace 3UNC expands brain imaging study of infants at risk for autism 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Cyno macaque plasma and serum - various quantities available...
Biology Products: